David A. Siegel Arbutus Biopharma Corp Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 17,600 shares of ABUS stock, worth $54,384. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,600

Previous 31,000 43.23%

Holding current value

$54,384

Previous $77,000 41.56%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.26 - $2.92 $30,283 - $39,128	-13,400 Reduced 43.23%	17,600 $45,000
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $52,390 - $78,740	31,000 New	31,000 $77,000
Q2 2023 Aug 14, 2023	BUY	$2.24 - $3.06 $30,688 - $41,922	13,700 New	13,700 $31,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $340,164 - $544,606	-171,800 Reduced 72.73%	64,400 $175,000
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $261,602 - $430,238	-108,100 Reduced 31.4%	236,200 $704,000

Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $710,635 - $1.05 Million	228,500 Added 197.32%	344,300 $1.34 Million
Q3 2021 Nov 15, 2021	SELL	$2.65 - $4.62 $288,320 - $502,656	-108,800 Reduced 48.44%	115,800 $497,000
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $491,500 - $690,066	-196,600 Reduced 46.68%	224,600 $681,000
Q1 2021 May 17, 2021	BUY	$3.14 - $4.84 $1.32 Million - $2.04 Million	421,200 New	421,200 $1.4 Million
Q4 2020 Feb 16, 2021	SELL	$2.76 - $4.97 $66,516 - $119,777	-24,100 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$1.75 - $6.2 $249,550 - $884,120	-142,600 Reduced 85.54%	24,100 $75,000
Q2 2020 Aug 14, 2020	BUY	$0.91 - $2.36 $29,757 - $77,172	32,700 Added 24.4%	166,700 $303,000
Q1 2020 May 15, 2020	BUY	$1.01 - $3.42 $53,530 - $181,260	53,000 Added 65.43%	134,000 $135,000
Q4 2019 Feb 14, 2020	BUY	$0.87 - $2.89 $1,479 - $4,913	1,700 Added 2.14%	81,000 $225,000
Q3 2019 Nov 14, 2019	SELL	$1.34 - $2.4 $9,514 - $17,040	-7,100 Reduced 8.22%	79,300 $121,000
Q2 2019 Aug 14, 2019	BUY	$1.46 - $4.44 $74,168 - $225,552	50,800 Added 142.7%	86,400 $180,000
Q1 2019 May 15, 2019	BUY	$3.41 - $4.57 $65,472 - $87,744	19,200 Added 117.07%	35,600 $127,000
Q4 2018 Feb 14, 2019	BUY	$3.5 - $9.66 $8,050 - $22,218	2,300 Added 16.31%	16,400 $63,000
Q3 2018 Nov 14, 2018	BUY	$7.85 - $12.35 $110,685 - $174,135	14,100 New	14,100 $133,000

Others Institutions Holding ABUS

# of Institutions

130

Shares Held

82.2M

Call Options Held

4.82M

Put Options Held

546K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $463M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account